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Abstract
Introduction: Over the last few years, many private companies are advertising direct-to-consumer genetic testing (DTC GT), mostly with no or 
only minor clinical utility and validity of tests and without genetic counselling. International professional community does not approve provision of 
DTC GT and situation in some EU countries has been analysed already. The aim of our study was to analyse current situation in the field of DTC GT in 
Slovenia and related legal and ethical issues. 
Materials and methods: Information was retrieved through internet search, performed independently by two authors, structured according to 
individual private company and the types of offered genetic testing.
Results: Five private companies and three Health Insurance Companies offer DTC GT and it is provided without genetic counselling. Available tests 
include testing for breast cancer, tests with other health-related information (complex diseases, drug responses) and other tests (nutrigenetic, an-
cestry, paternity). National legislation is currently being developed and Council of Experts in Medical Genetics has issued an opinion about Genetic 
Testing and Commercialization of Genetic Tests in Slovenia.  
Conclusions: Despite the fact that Slovenia has signed the Additional protocol to the convention on human rights and biomedicine, concerning 
genetic testing for health purposes, DTC GT in Slovenia is present and against all international recommendations. There is lack of or no medical su-
pervision, clinical validity and utility of tests and inappropriate genetic testing of minors is available. There is urgent need for regulation of ethical, 
legal, and social aspects. National legislation on DTC GT is being prepared. 
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Direct-to-consumer genetic testing (DTC GT) re-
fers to genetic testing advertised and offered di-
rectly to consumers outside the traditional health-
care system. In line with tremendous progress in 
genetic/genomic research leading to more and 
more genetic tests with potential predictive health 
information, private companies have found their 
niche in DTC GT. In the last few years, numerous 
private companies are emerging offering genetic 
tests without adequate pre- and post-test genetic 
counselling and mostly with no or minor clinical 
validity and clinical utility. A diverse selection of 
such DTC genetic tests are currently being offered 
to the public, including non-invasive prenatal test-
ing (NIPT) for Down syndrome, diagnostic tests for 
monogenic disorders, (preconception) carrier 
tests, tests for detecting predisposition to com-
mon complex disorders, pharmacogenomic tests, 
nutrigenomic tests, tests profiling a risk to addic-
tion and ancestry tests (1,2). 
Claims that private companies make about offered 
DTC genetic tests are often unsupported by scien-
tific evidence, mostly exaggerated, and may gen-
erate false expectations regarding the benefits of 
testing and lead to unwarranted decisions on the 
basis of test results. In addition, there is mostly no 
medical doctor specialized in clinical genetics in-
volved in DTC GT and it involves inappropriate ge-
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netic testing of minors (3,4). Individuals are not in-
formed/counselled before or after taking the ge-
netic test which is against all international recom-
mendations and guidelines on genetic testing. 
Even more, testing of minors is not only against 
guidelines but also unethical.
Regulatory framework of DTC GT in Europe is not 
unified and national legislations are not present in 
most of the countries (1,5). On the contrary, only a 
few EU countries have addressed DTC GT in their 
national legislation. For example, France, Germa-
ny, Portugal and Switzerland have specified in 
their legislation that genetic testing can only be 
indicated and performed by a medical doctor and 
only after adequate genetic counselling and ob-
tainment of consent of the person being tested. 
On the other hand, provision of DTC GT is allowed 
in Belgium and the United Kingdom. It is impor-
tant to emphasize that these countries only regu-
late DTC genetic tests nationally and their legisla-
tions have no influence on DTC tests offered 
through world-wide-web from other EU countries 
or from USA. Therefore consumers can still be 
reached from other countries through internet of-
fers. National legislation concerning DTC GT in Slo-
venia is currently being developed and Council of 
Experts for Medical Genetics has issued An opin-
ion about Genetic Testing and Commercialization 
of Genetic Tests in Slovenia (6). On the other hand, 
when clinical genetic testing is indicated and or-
dered by medical doctor, this is a part of National 
health care system in Slovenia, and testing is cov-
ered by basic health insurance. Laboratories, that 
perform these tests, fulfil the rules set down in the 
document Rules on the conditions that must be 
met by laboratories to carry out investigations in 
the field of laboratory medicine, issued by Ministry 
of Health (7). Also, they are listed in the Orphanet 
directory of medical laboratories providing genet-
ic tests (8). 
The aim of our study was to analyse current situa-
tion in the field of DTC GT in Slovenia (types of 
tests, number of companies and their offers, mar-
keting) and related legal and ethical issues. 
Materials and methods
Searching for information
Internet search was employed to identify currently 
offered DTC genetic tests. Using Google search en-
gine and key search term direct to consumer in 
combination with genetic testing, DNA testing/test, 
online DNA test, saliva DNA test, DNA kit, home DNA 
we searched national web pages. All retrieved sites 
and documents were checked in order to extract 
data. In order to avoid loss of information, two of 
the authors performed this search independently. 
Described searches were performed in the Febru-
ary 2014 and repeated in October 2014. The types 
of genetic testing offered, advertised benefits and 
aims as well as accompanying services were exam-
ined. 
Types of genetic tests, offered directly to 
consumers
DTC genetic tests currently present in Slovenian 
market can be categorized in three groups for the 
purpose of this review: 1) the group of tests with 
potential clinical utility, such as testing for mono-
genic inherited form of breast cancer, BRCA1 and 
BRCA2 genes; 2) the group of tests with other 
health related information, such as test related to 
complex diseases or drug responses; 3) other DTC 
tests, such as nutrigenetic tests, ancestry tests, pa-
ternity tests, specific traits tests. Details on first 
two groups are presented in this review. The third 
group was not included in present analysis since 
we focused on genetic tests related to health/dis-
ease implications.
Results
Conceptual categories in which DTC tests are 
offered
The types and conceptual categories of DTC ge-
netic tests in Slovenia are presented in table 1.
The most represented group of tests is presymp-
tomatic /susceptibility test for adults. These tests 
are usually advertised separately for women, for 
men, for managers and they involve susceptibility 
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testing for number of adult onset diseases. As a re-
sult of DNA analysis the patient receives his/her 
personal report or personal genetic book with 
guidelines for preventive actions. 
In addition, CardioRISQ test for assessment of risk 
for development of cardiovascular disease is of-
fered by one private company (testing for 8 low 
penetrance mutations in 5 genes: ApoE (apolipo-
protein E), MTHFR (methylenetetrahydrofolate re-
ductase), FII (coagulation factor II), FV (coagulation 
factor V Leiden) and HFE (hemochromatosis)) (9).
Presymptomatic testing for minors is also offered, 
and it includes testing for susceptibility for celiac 
disease, lactose intolerance, diabetes type 1 and 2, 
obesity, heart attack, hypertension, osteoporosis. 
This category includes also DTC GT offers for baby 
or child packages where one can test his child for 
his genetic propensity to develop diseases (above 
mentioned) and also his genetically determined 
physical features (e.g. sports and orientation, 
learning from mistakes etc.), his development, tal-
ents and professional guidelines (10–13). 
Another big group of test is DNA analysis for indi-
vidual’s response to pharmacological substances 
used for therapy of depression, high blood pres-
sure, high cholesterol levels, diabetes and some 
Type of test Details Conceptual category / Marketing strategy
Private company 
(Reference)*
Test with potential 
clinical utility
Specific mutations in BRCA1, BRCA2 
(monogenic inherited form of breast 
cancer)
presymptomatic /susceptibility test 
for adults 1/5 (11)
Test for other health 
related information – 
complex diseases








different types of cancer (bladder 
cancer, breast cancer, colorectal cancer, 
lung cancer, ovarian cancer, prostate 
cancer, skin cancer, stomach cancer)
diabetes type 1 and 2
presymptomatic /susceptibility test 
for adults
advertised separately for women, for 
men, for managers
presymptomatic testing for minors 
(for specific diagnosis only - detailed 
in text) 
specific offers for babies (detailed in 
text)
5/5 (9–13)
Test for other health 
related information 
















advertised separately for women, for 
men, for managers
5/5 (9–13)
Test not related to health/
disease information
nutrigenetic tests, ancestry tests, 
paternity tests Not analyzed in current article
Not analyzed in 
current article
*Number of private companies, offering the test, out of 5, currently present in Slovene market.
Table 1. Types and conceptual categories of DTC genetic tests in Slovenia.
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other diseases. In addition, one of DTC providers 
subspecializes in cancer disorders (myRISK pathol-
ogy supported genetic tests) and offers testing af-
ter diagnosis of breast cancer (prognosis indica-
tors, response to treatment, risk of recurrence, 
types of cancer, level of estrogen, progesterone 
HER2 receptors) and testing after diagnosis of 
colorectal cancer (relapse risk assessment). Also, 
multiplex DNA test for individuals previously diag-
nosed with multiple sclerosis is offered, stating 
that it assesses genetic and lifestyle risk factors in 
relation to the metabolic profile of each patient, 
taking into account relevant gene-drug (pharma-
cogenetic) and gene-diet (nutrigenetic) interac-
tions (9).  
Provision of DTC genetic testing
In Slovenia, there are currently 5 commercial com-
panies offering DTC genetic testing (9–13). None of 
Slovenian DTC companies is listed as part of Slove-
nian healthcare system and no DTC services are 
covered by National Health Insurance Company. 
Their laboratories are not a part of nationally regu-
lated system and do not comply to the document 
on Rules on the conditions that must be met by 
laboratories to carry out investigations in the field 
of laboratory medicine, issued by Ministry of 
Health (7). According to web pages of DTC GT pro-
viders, some of the laboratories are outside of Slo-
venia and for some, there are no publicly available 
details at all (9–13). There is no pre-test counselling 
involved. Post-test counselling, performed by 
“specialized experts in the field of medicine and 
pharmacy“ (cited from webpage of private compa-
nies) is or is not included, depending on the test 
and company. None of the DTC GT providers offer 
genetic counselling by the experts trained and li-
censed for clinical genetics in Slovenia according 
to the data available on their web pages and Med-
ical chamber of Slovenia (14). DNA analysis comes 
in form of personalized report with action plan for 
healthy nutrition and prevention (also for babies). 
Some companies advertise partnership with sev-
eral private medical practices. 
In addition, in Slovenia, there are currently 3 Health 
Insurance Companies offering DTC GT as an added 
value when buying a health insurance policy. Pro-
viders declare confidentiality of genetic data that 
cannot be accessed by Health Insurance Company 
for any other purpose. Tests are offered in collabo-
ration with one of the 5 DTC GT companies. 
Advertising of DTC genetic testing
DTC GT is often advertised as testing of a well-
known correlation between defects in certain 
genes and diseases and clear guidelines for pre-
ventive actions given by a doctor specialist (10). A 
statement from DTC companies declares that a 
comprehensive genetic analysis will determine in-
dividual’s susceptibility to common diseases and 
provide preventive measures (12). They also state 
that their primary mission is to use the scientific 
discoveries in the field of genetics for creating a 
better and healthier life for individuals and their 
families (10). Majority of these statements are mis-
leading and untrue and are advertised in order to 
promote test uptake and generate profit. Mislead-
ing statements create unreal consumer’s expecta-
tions and generate false certainty about test re-
sults.   
Discussion
There are five private providers of DTC GT in Slove-
nia, the legislation on the subject is still under de-
velopment and the public awareness of utility and 
significance of DTC testing is probably low. Al-
though there is no specific law on DTC GT in Slove-
nia, our country has signed and ratified an Addi-
tional protocol to the convention on human rights 
and biomedicine in 2008, concerning Genetic testing 
for health purposes, adopted by Council of Europe 
(15,16). Also, Council of Experts for Medical Genet-
ics has issued “An opinion about Genetic Testing 
and Commercialization of Genetic Tests in Slove-
nia” (6).
Main drawbacks related to DTC GT are the lack of 
medical supervision, scientific accuracy, clinical va-
lidity and utility of DTC genetic testing results and 
their interpretation (statistical risk assessment of 
genetic risk in multifactorial diseases where com-
plex interactions of different genetic and environ-
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mental risk factors are involved) as well as inap-
propriate genetic testing of minors. Control of 
both pre and postanalytical requirements is poor 
and outside national or international regulations. 
In addition, DTC genetic test providers declare 
confidentiality of genetic data but possibility of 
discrimination if privacy is not maintained is still 
an important issue (17,18). Described situation in 
Slovenia is comparable to the current issues in oth-
er European countries (1,19,20). In addition, none 
of DTC GT providers laboratory is a part of nation-
ally regulated system. Moreover, majority of the 
tests are performed outside of Slovenia, which 
makes it very hard or impossible to control.
There is no general agreement on scientific validi-
ty of the tests, their health and ethical implications 
and their legal status, although scientific commu-
nity agrees with the fact that there is very limited 
or no clinical utility and validity of most of DTC 
tests (2,19–24). Even more critical is the fact, that 
proper genetic counselling is not part of any DTC 
GT in Slovenia, although genetic counselling is a 
crucial part of the process of any genetic testing, 
recommended by Council of Europe and all pro-
fessional societies worldwide (25,26). Some Euro-
pean countries already have a law on genetic test-
ing and all of them stated that genetic testing is 
only applicable for medical purposes and should 
be supported by genetic counselling and clinical 
genetic services. This is also supported by most of 
European clinical geneticists - generally, they are 
against the currently widespread way of offering 
DTC GT for specific severe or late onset diseases 
(2).  
Another important issue is DTC testing performed 
in children. Commercial companies offer testing 
for adult onset diseases also in children, which 
raises number of ethical, legal and social issues 
(19). The European Society of Human Genetics 
(ESHG) recommends genetic testing on a person 
who does not have the capacity to consent only if 
it is for his or hers direct benefit. Therefore, for pre-
dictive genetic testing to be performed in minors, 
a considerable risk for inheriting a disease must 
exist and therapeutic or preventive measures must 
be available.  
Last but not least, results of DTC GT do not consid-
er individuals family history. Analyzing only cer-
tain genetic variants and not considering family 
history impact on absolute risk may result in false 
sense of security. At the same time, the results may 
raise unjustified worries and create stress by dis-
claiming inaccurate risks. 
The European Society of Human Genetics (ESHG) 
opposed premature DTC commercialization of var-
ious genetic tests, stating “predictive value must 
be sufficient to meet the standards for clinical use. 
Clinical utility of a genetic test should be an essen-
tial criterion for deciding to offer this test to a per-
son” (20). None of current DTC genetic test offers 
in Slovenia meets these criteria. It is widely be-
lieved that, unfortunately, currently offered DTC 
GT is only a messenger of forecoming wide availa-
bility of whole genome sequencing of individuals 
(17). Prices for individual’s exome or genome se-
quencing are dropping and their clinical validity 
and utility is increasing. With extensive genomic 
profiling being more available important issues 
will be raised. The ways to regulate ethical, legal, 
social in addition to clinical issues need to be dis-
cussed and set down, also with respect to the field 
of DTC GT. 
In conclusion, there are five private companies of-
fering DTC GT in Slovenia. Despite the fact that 
Slovenia has signed the Additional protocol to the 
convention on human rights and biomedicine, 
concerning genetic testing for health purposes, 
there is lack of or no medical supervision, clinical 
validity and utility of DTC GT results and their in-
terpretation. Moreover, inappropriate genetic test-
ing of minors is available. There is urgent need for 
regulation of ethical, legal, and social aspects, in 
addition to clinical issues and National legislation 
concerning DTC GT is currently being developed 
in Slovenia.
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